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Bioinformatic identification and characterization
of human endothelial cell-restricted genes
Manoj Bhasin1,2, Lei Yuan2,3,4, Derin B Keskin5, Hasan H Otu2, Towia A Libermann1,2, Peter Oettgen2,3,4*

Abstract
Background: In this study, we used a systematic bioinformatics analysis approach to elucidate genes that exhibit
an endothelial cell (EC) restricted expression pattern, and began to define their regulation, tissue distribution, and
potential biological role.
Results: Using a high throughput microarray platform, a primary set of 1,191 transcripts that are enriched in
different primary ECs compared to non-ECs was identified (LCB >3, FDR <2%). Further refinement of this initial
subset of transcripts, using published data, yielded 152 transcripts (representing 109 genes) with different degrees
of EC-specificity. Several interesting patterns emerged among these genes: some were expressed in all ECs and
several were restricted to microvascular ECs. Pathway analysis and gene ontology demonstrated that several of the
identified genes are known to be involved in vasculature development, angiogenesis, and endothelial function
(P < 0.01). These genes are enriched in cardiovascular diseases, hemorrhage and ischemia gene sets (P < 0.001).
Most of the identified genes are ubiquitously expressed in many different tissues. Analysis of the proximal
promoter revealed the enrichment of conserved binding sites for 26 different transcription factors and analysis of
the untranslated regions suggests that a subset of the EC-restricted genes are targets of 15 microRNAs. While
many of the identified genes are known for their regulatory role in ECs, we have also identified several novel ECrestricted genes, the function of which have yet to be fully defined.
Conclusion: The study provides an initial catalogue of EC-restricted genes most of which are ubiquitously
expressed in different endothelial cells.

Background
The endothelium, which lines the inner surface of all
blood vessels, participates in several normal physiological functions including control of vasomotor tone, the
maintenance of blood fluidity, regulation of permeability,
formation of new blood vessels, and trafficking of cells
[1]. The endothelium also plays an important role in
several human diseases. In the setting of inflammation
several genes become activated within the endothelium
to facilitate the recruitment, attachment, and transmigration of inflammatory cells. Over time, however, in
chronic inflammatory diseases EC responses become
impaired, leading to EC dysfunction.
As a cell type, ECs exhibit tremendous heterogeneity
[2]. For example, there are significant differences in EC
structure and function based on the size and type of
* Correspondence: joettgen@bidmc.harvard.edu
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blood vessel, from larger arteries or veins, to medium
sized arterioles or venules, down to capillary ECs. There
is also significant heterogeneity at the level of a particular tissue or organ. For example, in the brain, the
endothelium plays a particularly important protective
role as part of the blood brain barrier with ECs that are
closely attached to one another forming a tight barrier
that is impermeable to the passage of even small solutes
or ions. In contrast, in the liver, the sinusoidal ECs are
fenestrated so that small to moderate size transcellular
pores promote the uptake of large lipid containing particles from the blood [3,4].
The endothelium is known to play an important role
in several human diseases including atherosclerosis, diabetes mellitus, and sepsis. The overall goal of the current study was to use primary and publicly available
microarray data from human ECs, non ECs, and tissues,
to identify genes that exhibit an EC-restricted pattern,
define their distribution in different tissues, and
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determine whether changes in the expression of any of
the genes are linked to particular diseases. Our study,
has for the first time, identified and ranked a significant
number of genes that exhibit an EC-restricted expression pattern. Among these genes, several interesting patterns of expression emerge. Whereas many of the genes
are expressed in all ECs, some are restricted to microvascular ECs. The vast majority of EC-restricted genes
are expressed in multiple tissues. The EC-restricted
genes were found to be associated with a number of different cellular functions including vasculature development, cell differentiation, and angiogenesis. Analysis of
the regulatory regions of the EC-restricted genes
demonstrated enrichment of binding sites for a selected
number of transcription factors and microRNAs.

Methods
Cell culture

HUVEC (human umbilical vein EC cell; Lonza), HAEC
(human aortic EC cells), HCAEC (human coronary artery
EC cells), HPAEC (human pulmonary artery EC cells),
and HMVEC (human microvascular (dermal) EC cell;
kindly provided by Dr. William Aird) were grown in
EBM-2 (EC Cell Basal Medium-2) supplemented with
EGM SingleQuots (Lonza). HASMC (human aortic
smooth muscle cell) were grown in SmBM Basal Medium
supplemented with SmGM-2 SingleQuot (Lonza). For the
isolation of the T and B cells, discarded leukocytes from
platelet donations by healthy human donors were used in
this study. Samples were obtained from subjects after
informed consent was obtained using an institutionally
approved protocol (IRB protocol 2005-P-001364/2). Red
blood cells were removed using Ficoll-Paque PLUS
according to manufacturer’s protocol. (GE-Healthcare.
Uppsala Sweden). Donor Peripheral Blood Mononuclear
Cells (PBMC) were stained with pan T-cell specific CD3PE and pan B-cell specific CD20-FITC antibodies. Fluorescently labeled cells were sorted using a high speed cell
sorter. (FACS Aria. BD biosciences San Jose. California).
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of genes called present, 3’ to 5’ ratios for beta-actin and
GAPDH and values for spike-in control transcripts [6].
We also checked for reproducibility of the samples by
using chip to chip correlation and signal-to-noise ratio
(SNR) methods for replicate arrays. All the high quality
arrays were included for low and high level bioinformatics analysis. Primary gene expression data are publicly available at GEO http://www.ncbi.nlm.nih.gov/geo/
in GSE21212.
Statistical Analysis

To obtain the signal values, high quality chips were
further analyzed by dChip, as it is more robust than
MAS5.0 and RMA in signal calculation. The raw probe
level data was normalized using smoothing-spline invariant set method. The signal value for each transcript
was summarized using PM-only based signal modeling
algorithm described in dChip. The PM only based modeling based algorithm yields less number of false positives as compared to the PM-MM model. In this way,
the signal value corresponds to the absolute level of
expression of a transcript[7]. These normalized and
modeled signal values for each transcript were used for
further high level bioinformatics analysis. During the
calculation of model based expression signal values,
array and probe outliers are interrogated and image
spikes are treated as signal outliers.
When comparing two groups of samples to identify
genes enriched in a given phenotype, if the 90% lower
confidence bound (LCB) of the fold change (FC)
between the two groups was above 3 and median false
discovery rate is <2%, the corresponding gene was considered to be differentially expressed [8]. LCB is a stringent estimate of FC and has been shown to be the
better ranking statistic [9]. It has been suggested that a
criterion of selecting genes that have an LCB above 2.0
most likely corresponds to genes with an “actual” fold
change of at least 3 in gene expression [8,10].
Identification of EC-restricted genes

RNA isolation

Total RNA was isolated using the RNAeasy kit (QIAGEN) following the manufacturer’s instructions.
Microarray Analysis

Transcriptional profiling of endothelial and non-EC cells
was performed using the Affymetrix oligonucleotide
microarray HT U133 plate with 24 chips according to a
standard Affymetrix protocol for cDNA synthesis, in
vitro transcription, production of biotin-labeled cRNA,
hybridization of cRNA with HT Plate A and B, and
scanning of image output files [5]. The quality of hybridized chips was assessed using Affymetrix guidelines on
the basis of average background, scaling factor, number

The list of differentially expressed genes obtained from
the primary analysis (previous section) was further analyzed through a series of steps to obtain EC-restricted
genes. This analysis was performed using the following
three steps, i); determination of the enrichment score,
ii); performing an outlier analysis, and iii); ranking the
genes according to EC specificity.
i) Enrichment Score [ECS]

The enrichment analysis was performed to determine
the probability that genes are specifically over expressed
in ECs as compared to other primary non-ECs. For this
analysis we used the public REFEXA database http://
www.lsbm.org/site_e/database/index.html. The REFEXA
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database consists of gene expression data from a series
of primary cells, cancer cell lines, and tissues. The
MAS5 normalized data was manually obtained from the
database for all the transcripts that were identified as
highly expressed in ECs compared to non-ECs in the
primary analysis. The enrichment score of each gene
was determined by calculating the relative expression in
the ECs compared to non-ECs. Each transcript was
assigned a present/absent call in every primary cell on
the basis of expression value. The transcript is called
present (P) in a primary non-endothelial cell if it was
expressed >50% of the expression level in the primary
ECs, otherwise it was called absent (A). The EC score
(ECS) is obtained using the following equation:
ECS j =

∑

n
i =0

Ai / (Pi + Ai)

(1)

where ECSj is the enrichment score for a transcript j,
Ai and Pi are the present and absent calls for the transcript in different normal primary cells (n).
ii) Outlier Analysis

The outlier analysis was performed on the list of genes
obtained after step i) for the selection of genes with
restricted EC expression. The outlier analysis was performed by means and standard deviation of the expression values using publicly available microarray data. If
the expression of a given transcript in a sample falls 2
standard deviations outside of the mean expression in
the distribution obtained using all samples, the particular
sample is considered as an outlier. If the cluster of the
outliers consists only of ECs, the genes were considered
as good candidates for being EC-restricted. On the contrary, if the cluster of the outliers consists of ECs and
non-ECs, these genes were considered to have less specificity for ECs and were filtered out from the final analysis.
iii) Ranking of EC-restricted genes

After the outlier and enrichment analysis, all the identified EC-restricted genes were ranked on the basis of
average fold change of a gene in ECs as compared to
non ECs (REF_FOLD) in publicly available datasets
(REFEXA) and Fold change between ECs and non-ECs
from our primary experiment (FC) [EQ 2]. The genes
with high REF_FOLD and high FC are considered to be
more EC-restricted and assigned a higher rank.
Rank i = REF _ FOLD i × FC i

(2)

where REF_FOLD = (Expression in ECs in public set/
Expression in Non-EC) and FC = (Expression in ECs in
primary set/Expression in Non-EC).
To further reduce the false positive rate, we have
selected the top 60% of the transcripts with greater than

3 fold expression in ECs compared to non-ECs as good
candidates for endothelial restriction.
Pathways, Gene ontology and Disease set enrichment
analysis of EC-restricted genes

The functional analysis of the EC-restricted genes was
performed in terms of canonical pathways, disease sets
and gene ontology (GO) categories. The canonical pathways and disease set enrichment analysis was performed
using the MetaCore tool of GeneGo package http://
www.genego.com/. It consists of manually curated information about gene regulation, protein interactions, and
metabolic and signaling pathways. The overrepresented
canonical pathways and disease biomarker sets were
ranked on the basis of P values obtained using the
Simes procedure accounting for multiple hypothesis
testing representing the probability of mapping arising
by chance, based on the number of EC-restricted genes
identified in a particular canonical pathway or disease
compared to the total number of genes in the GO category/Disease set. The Go categories/Disease set with a
False Discovery Rate (FDR) corrected P value <0.05
were considered significant.
The Database for Annotation, Visualization and Integrated Discovery (DAVID) was used to identify overrepresented gene ontology categories form the
endothelial restricted genes [11]. DAVID is an online
implementation of the EASE software that produces the
list of overrepresented categories using jackknife iterative resampling of the Fisher exact probabilities. A score
was assigned to each category by using “-log” of EASE
score to show the significantly enriched gene ontology
categories. The related gene ontology categories were
merged into a cluster using the functional clustering
module of DAVID. Higher enrichment scores for particular genes reflect increasing confidence in their overrepresentation.
Analysis of transcription factor binding sites

Recent improvements in bioinformatics methods for
the analysis of sequences regulating transcription have
made it possible to elucidate potential factors involved
in regulating key regulatory networks underlying a
transcriptional response. We divided the EC specific
genes into two sets on the basis of K Mean clustering
for promoter analysis i) high expression in all ECs ii)
and high expression in HMVEC. The promoter analysis was performed separately on these two sets using
the online tool ExPlain http://explain.biobase-international.com/cgi-bin/biobase/ExPlain_2.4.2/ for detection
of over-represented transcription factor binding sites.
ExPlain uses the MatchTM, a weight matrix-based tool
for searching putative transcription factor binding sites
[12,13].
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For the analysis, we selected regions from 2000 bp
upstream to 100 bp downstream of the transcription
start site of each gene (Yes set). The enrichment was
obtained against a random set of promoters obtained
from human housekeeping genes (No set). The entire
vertebrate non-redundant set of transcription factors
matrix from transfac database was used for scanning
potential binding sites [14]. The matrices that did not
differ much in density between the positive and negative
set were removed from the results. A significant overrepresentation of a transcription factor binding site in a
target set as compared to the background set was determined using a 1-tailed Fisher exact probability test [P
value < 0.01,FC (yes_set/no_set) > 1.2). After completion
of the enrichment analysis, the transcription factor binding sites for each set were compared with each other, in
order to identify TF binding sites that were common
and distinct among the different types of ECs (e.g. all,
microvascular).
MicroRNA target analysis

Another potential mechanism of regulating EC specific
genes could be through miRNA, a class of small noncoding RNAs, that regulate gene expression primarily
through post-transcriptional repression by promoting
mRNA degradation in a sequence-specific manner [15].
We were interested in identifying whether miRNA binding sites are enriched in EC-restricted genes. Computational analysis of the miRNA targets sites was
performed using Composite Regulatory Signature Database (CRSD) http://140.120.213.10:8080/crsd/main/
home.jsp, a comprehensive server for composite regulatory signature discovery. CRSD has a package for prediction of miRNA binding sites by searching the UTRs
for segments of perfect Watson-Crick in the 3’UTR of
the target gene set [16].The miRNA binding sites for
each of the micro RNA are calculated in the ECrestricted set and the background set (54,576 genes
from human unigenes). The enrichment of each miRNA
binding site is calculated on the basis of its abundance
in the EC-restricted set and the background set. The
significance of enrichment is expressed as a P value
(smaller the P value more significant is the enrichment).
Tissue specificity of EC specific Gene

In order to determine the normal tissue distribution of
the EC specific genes, we obtained the normalized
expression level from the Stanford Source database [17].
Source database presents the relative expression level of a
gene in different tissues that is normalized for the number of samples from each tissue included in UniGene.
The gene expression information for the different transcripts was obtained from dbEST expression profile.
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In addition to relative gene expression information
from the Source database, we have also manually
curated the protein expression information about the
endothelial specific genes from the Human Protein
Atlas database. The Human Protein Atlas is a comprehensive database that provides the protein expression
profiles for a large number of human proteins, presented as immunohistological images from most human
tissues [18,19]. It contains antibody-based protein
expression and localization profiles of >4,000 proteins in
48 normal human tissues and 20 different cancers [20].
The expression level of each protein is presented in a
four color scale system that takes into consideration the
intensity of the protein expression and quantity of positive images tested for each protein. It is a very useful
tool to extract the relative expression level of proteins in
different tissues.
Quantitative real-time PCR

Total RNA was isolated using the RNAeasy kit
(QIAGEN, Valencia, CA). Single stranded cDNA was
synthesized from total RNA using High Capacity RNAto-DNA Kit (Applied Biosystems). SYBR Green I-based
real-time PCR was carried out on an Opticon Monitor.
The sequences of the primers used in this study are
listed in Additional File 1. For normalization of each
sample, human specific TATA-binding protein (TBP)
primers were used to measure the amount of TBP
cDNA.

Results
Identification of EC-restricted genes

In an effort to identify genes that exhibit an ECrestricted pattern total RNA was isolated from primary
cultured ECs (including HUVEC, HPAEC, HAEC,
HMVEC, and HCAEC) and non-ECs (HASMC, B cells,
T cells). Gene expression profiling was performed using
a high throughput platform, HT U133 plate, that measures more than 43,000 well-characterized genes and
UniGene clusters. The expression profiling was performed in duplicate. All the array data was determined
to be of high quality as assessed by the scaling factor,
average background, percent present calls, and 3’/5’RNA
ratio. After normalization and preprocessing of the data,
we generated a list of genes that are significantly differentially expressed between different ECs and non-ECs.
The heterogeneity in the transcription profile of the EC
was identified using unsupervised clustering, reflecting
the global similarities between the samples [Figure 1A].
Unsupervised clustering demonstrated the highest similarity within the biological replicates and the least similarity between ECs and non-ECs. The cladogram
produced by unsupervised clustering depicted that
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Figure 1 Overall approach for extraction of endothelial restricted genes. A) Unsupervised Pearson Correlation based cluster of different EC
and non-EC arrays after normalizing the data. ECs (HMVEC, HUVEC, HPVEC, HAEC, and HCEAC) form separate clusters from non-ECs (HSAMC, B
Cells, T Cells). In most of cases biological replicates of each cell type have better correlation with each other than with other cell types. B) Venn
diagram indicating overlap between microvascular, arterial and venous endothelial differentially expressed genes obtained from the primary
analysis C) Schematic representation of the approach for identifying the genes with EC-restricted expression (EC-restricted) D) Venn diagram
depicting the overlap between microvascular, arterial and venous endothelial restricted transcripts.

venous and pulmonary arterial ECs are much closer in
expression profile as compared to microvascular cells.
Comparing groups, we found 1,713 transcripts that are
differentially expressed in HMVEC compared to nonECs (LCB > 3 and FDR < 2%). Similarly for HUVEC
and HPVEC, 1,534 and 1,539 transcripts were respectively differentially expressed compared to non-ECs. For
the arterial EC cells, 1,239 HCAEC and 1,316 HAEC
transcripts were determined to be differentially

expressed in these cells compared to non-ECs. Comparison of the differentially expressed transcripts in microvascular (HMVEC), venous (HUVEC, HPVEC) and
arterial (HAEC, and HCAEC) cells using Venn diagrams
revealed that approximately half of the transcripts are
differentially expressed in all three EC types. However
we also observed that each EC type possessed a unique
expression signature; the differential expression of transcripts was limited to one type of EC [Figure 1B].
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Table 1 List of the endothelial restricted genes with detailed annotation and rank score
Probe

Gene Symbol

UGCluster

FC

REFEXA_FC

Rank

205612_at

MMRN1

Hs.268107

172.65

64.625

11157.50625

204482_at

CLDN5

Hs.505337

124.75

47.5625

5933.421875

202112_at

VWF

Hs.440848

61.15

78.05172414

4772.862931

206464_at

BMX

Hs.495731

55.28

80.46153846

4447.913846

205572_at

ANGPT2

Hs.583870

69.88

20.21875

1412.88625

204904_at

GJA4

Hs.296310

37.23

34.5

1284.435

204677_at

CDH5

Hs.76206

79.89

13.96610169

1115.751864

204468_s_at
226028_at

TIE1
ROBO4

Hs.78824
Hs.524121

78
34.97

14.19626168
27.89130435

1107.308411
975.358913

227779_at

ECSCR

Hs.483538

53.73

12.03448276

646.6127586

222856_at

APLN

Hs.303084

76.9

8.106666667

623.4026667

207526_s_at

IL1RL1

Hs.66

64.53

9.56846473

617.453029

204134_at

PDE2A

Hs.503163

43.51

13.72368421

597.1175

214319_at

FRY

Hs.507669

38.96

15.2962963

595.9437037

219059_s_at

LYVE1

Hs.655332

88.96

6.384615385

567.9753846

201785_at
236262_at

RNASE1
MMRN2

Hs.78224
Hs.524479

28.82
28.44

18.38461538
18.28571429

529.8446154
520.0457143

204818_at

HSD17B2

Hs.162795

133.64

3.846938776

514.104898

220637_at

FAM124B

Hs.147585

17.93

23.09090909

414.02

229902_at

FLT4

Hs.646917

19.45

20.94594595

407.3986486

205392_s_at

CCL14

Hs.714858

45.05

8.48

382.024

223567_at

SEMA6B

Hs.465642

17.28

21.82608696

377.1547826

211273_s_at

TBX1

Hs.173984

35.43

10.18181818

360.7418182

213715_s_at
222885_at

KANK3
EMCN

Hs.322473
Hs.152913

34.78
36.24

10.23076923
8.930555556

355.8261538
323.6433333

206331_at

CALCRL

Hs.470882

44.19

7

309.33

225369_at

ESAM

Hs.173840

14.83

20.10714286

298.1889286

219837_s_at

CYTL1

Hs.13872

47.07

5.946969697

279.9238636

241926_s_at

ERG

Hs.473819

79.8

3.44

274.512

238488_at

LRRC70

Hs.482269

12.1

21

254.1

203934_at

KDR

Hs.479756

40.75

6.224137931

253.6336207

227923_at
225817_at

SHANK3
CGNL1

Hs.149035
Hs.148989

15.6
27.25

12.96296296
7.260869565

202.2222222
197.8586957

229002_at

FAM69B

Hs.495480

26.39

7.414634146

195.6721951

228489_at

TM4SF18

Hs.22026

53.73

3.328

178.81344

210082_at

ABCA4

Hs.416707

16.65

9.857142857

164.1214286

235334_at

ST6GALNAC3

Hs.337040

24.36

6.659090909

162.2154545

229309_at

ADRB1

Hs.99913

19.91

7.891891892

157.1275676

235044_at

CYYR1

Hs.37445

23.53

5.6

131.768

205569_at
229233_at

LAMP3
NRG3

Hs.518448
Hs.125119

14.72
19.5

8.56
6.285714286

126.0032
122.5714286

235050_at

SLC2A12

Hs.486508

17.4

6.363636364

110.7272727

220027_s_at

RASIP1

Hs.233955

16.99

6.03125

102.4709375

204683_at

ICAM2

Hs.431460

9.09

11.23245614

102.1030263

220300_at

RGS3

Hs.494875

29.92

3.411764706

102.08

206283_s_at

TAL1

Hs.705618

24.65

4.097222222

100.9965278

227307_at

TSPAN18

Hs.385634

7.32

13.53333333

99.064

206210_s_at
228601_at

CETP
LOC401022

Hs.89538
Hs.98661

7.91
12.94

12.33333333
7.36

97.55666667
95.2384

218825_at

EGFL7

Hs.91481

13.85

6.789473684

94.03421053

211518_s_at

BMP4

Hs.68879

28.88

3.243243243

93.66486486
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Table 1 List of the endothelial restricted genes with detailed annotation and rank score (Continued)
229726_at

GRAP

Hs.567416

9.1

10.14285714

92.3

229376_at

PROX1

Hs.585369

26.82

3.338461538

89.53753846

204368_at

SLCO2A1

Hs.518270

17.02

5.051724138

85.98034483

230132_at
209543_s_at

ATP5SL
CD34

Hs.351099
Hs.374990

22.49
17.19

3.585106383
4.68115942

80.62904255
80.46913043

228311_at

BCL6B

Hs.22575

12.6

6.333333333

79.8

219568_x_at

SOX18

Hs.8619

3.72

21.42857143

79.71428571

218736_s_at

PALMD

Hs.483993

17.5

4.270072993

74.72627737

204681_s_at

RAPGEF5

Hs.174768

22.02

3.351851852

73.80777778

239665_at

LOC441179

Hs.719702

20.51

3.578947368

73.40421053

238846_at

TNFRSF11A

Hs.204044

11.24

6.416666667

72.12333333

222911_s_at
231887_s_at

CXorf36
KIAA1274

Hs.98321
Hs.202351

18.06
13.86

3.953703704
4.685185185

71.40388889
64.93666667

202411_at

IFI27

Hs.532634

8.4

7.202764977

60.50322581

205581_s_at

NOS3

Hs.647092

11.89

4.958333333

58.95458333

206481_s_at

LDB2

Hs.714330

18.81

3.117505995

58.64028777

224385_s_at

MOV10L1

Hs.62880

5.37

10.09090909

54.18818182

230250_at

PTPRB

Hs.434375

13.61

3.787878788

51.5530303

230673_at

PKHD1L1

Hs.170128

4.04

12.625

51.005

222908_at
240646_at

FAM38B
GIMAP8

Hs.585839
Hs.647121

7.79
8.59

6.5
5.7

50.635
48.963

231792_at

MYLK2

Hs.86092

13.89

3.5

48.615

208983_s_at

PECAM1

Hs.514412

9.63

4.606138107

44.35710997
43.74266667

51158_at

FAM174B

Hs.27373

12.38

3.533333333

214156_at

MYRIP

Hs.594535

3.08

12.88888889

39.69777778

205507_at

ARHGEF15

Hs.443109

11.7

3.202898551

37.47391304

218901_at

PLSCR4

Hs.477869

7.29

5.044217687

36.77234694

228342_s_at
219247_s_at

ALPK3
ZDHHC14

Hs.459183
Hs.187459

12.23
4.32

3
8.176470588

36.69
35.32235294

213552_at

GLCE

Hs.183006

10.2

3.446428571

35.15357143

205247_at

NOTCH4

Hs.436100

6.44

5.409090909

34.83454545

205003_at

DOCK4

Hs.654652

11.06

3.085365854

34.12414634

218711_s_at

SDPR

Hs.26530

8.83

3.822222222

33.75022222

201801_s_at

SLC29A1

Hs.25450

10.62

3.057324841

32.46878981

218995_s_at

EDN1

Hs.511899

9.37

3.31779661

31.08775424

206855_s_at
226636_at

HYAL2
PLD1

Hs.76873
Hs.382865

5.2
8.18

5.645502646
3.347826087

29.35661376
27.38521739

211177_s_at

TXNRD2

Hs.443430

6.85

3.825688073

26.2059633

228245_s_at

OVOS

Hs.524331

6.8

3.851485149

26.19009901

218805_at

GIMAP5

Hs.647079

4.08

6.153846154

25.10769231

233924_s_at

EXOC6

Hs.655657

6.79

3.680672269

24.99176471

223796_at

CNTNAP3

Hs.658328

7.27

3.396039604

24.68920792

220945_x_at

MANSC1

Hs.591145

8.04

3.065934066

24.65010989

230800_at
237466_s_at

ADCY4
HHIP

Hs.443428
Hs.507991

7.13
5.84

3.260869565
3.927492447

23.25
22.93655589

205635_at

KALRN

Hs.8004

4.8

4.657894737

22.35789474

240890_at

LOC643733

Hs.713751

3.71

5.5

20.405

213030_s_at

PLXNA2

Hs.497626

5.18

3.504761905

18.15466667

243337_at

FREM3

Hs.252714

3.42

4.461538462

15.25846154

226882_x_at

WDR4

Hs.248815

3.51

4.122807018

14.47105263

232080_at

HECW2

Hs.654742

4.02

3.578947368

14.38736842

210044_s_at

LYL1

Hs.46446

4.42

3.239669421

14.31933884
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Table 1 List of the endothelial restricted genes with detailed annotation and rank score (Continued)
205680_at

MMP10

Hs.2258

4.03

3.326693227

206222_at

TNFRSF10C

Hs.655801

3.29

3.714285714

12.22

219777_at

GIMAP6

Hs.647105

3.64

3.335664336

12.14181818

203650_at
222446_s_at

PROCR
BACE2

Hs.647450
Hs.529408

3.27
3.26

3.582278481
3.023094688

11.71405063
9.855288684

238036_at

SHE

Hs.591481

3.06

3.219512195

9.851707317

The total number of transcripts that are significantly
different in at least one of the EC types compared to
non-ECs consists of 2553, representing 1617 genes. To
further refine our initial list of EC-restricted genes, we
evaluated the expression of these genes using the data
from REFEXA http://www.lsbm.org/site_e/database/
index.html to identify EC-restricted genes. To calculate
an enrichment score for each gene, expression values
were manually obtained for each transcript using the
REFEXA database http://www.lsbm.org/site_e/database/
index.html. This database has MAS5 normalized gene
expression data for several primary cells, including ECs,
cancer cell lines, and normal tissues. For analysis we only
used the expression data for 30 primary cells and
excluded all cancer cell lines. The enrichment and outlier
analysis identified 289 outlier transcripts with an enrichment score of 1 (see methods for details). To further
reduce the number of false positive results, the top 60%
(168 transcripts) of transcripts with an average of greater
than or equal to 3 fold overexpression in EC cells as
compared to non-EC cells were considered EC-restricted.
The expression value of these 168 transcripts was manually checked and transcripts with reduced specificity were
removed. After manual inspection of relative expression
profiles of each transcript, we selected 152 transcripts
that correspond to 109 valid genes exhibiting an ECrestricted pattern (Table 1). The 152 transcripts with
varying EC specificity are ranked on the basis of fold
change in the primary set and fold change from the
external datasets (e.g. REFEXA). The Rank score is a significance level with larger rank scores indicating increasing confidence in endothelial restriction. The overall
schema of curating endothelial specific genes is shown in
Figure 1C. Many genes that are known to be ECrestricted, including angiopoietin-2, von Willebrand’s factor (vWF), VE-cadherin (CD144) are at the top of the list
(Table 1). Comparison of the EC-restricted transcripts in
microvascular (HMVEC), venous (HUVEC, HPVEC) and
arterial (HAEC, and HCAEC) cells using Venn diagrams
revealed that most of the transcripts are differentially
expressed in all three EC cell types. Only a small fraction
of transcripts are uniquely differentially expressed in
microvascular ECs [Figure 1D]. A colorogram demonstrating the expression pattern for each of the ECrestricted genes is shown in Figure 2. The colorogram

13.40657371

consists of a range of patterns from transcripts highly
expressed in all EC types (Pattern IV) to transcripts that
are highly expressed in particular EC types (Pattern I).
ANGPT2, TBX1, FLT4 are examples of genes that are
highly expressed in the HMVEC cells. The expression
patterns of EC-restricted genes were further confirmed
using the REFEXA dataset [Figure 3]. To further validate
the microarrays results, we used PCR to quantitate the
expression levels of 12 randomly selected EC-restricted
genes in primary ECs and non-ECs. A very similar ECrestricted expression pattern was observed for all 12
genes [Figure 4]. Although the relative fold enrichment
of some of the EC-restricted genes was somewhat lower
than initially identified by microarray analysis, the
expression in non-ECs remained quite low or absent in
comparison to ECs.
Pathways and Gene Ontology (GO) Processes modulated
by EC-restricted genes

We performed an enrichment analysis of the ECrestricted genes to identify the pathways and GO processes where the EC-restricted genes occur more often
than would be expected by random distribution. The
pathway enrichment analysis was performed using the
MetaCore tool of the GeneGO package where P values
of <0.05 (FDR adjusted) are considered significant. The
enrichment analysis identified a set of statistically significant enriched pathways (Figure 5A). The most highly
enriched pathways included “EC contacts by junctional/
nonjuctional mechanisms“, “Regulation of eNOS activity
in cardiomyocytes and endothelial cells“, “thrombospondin signaling“, “Role of PKA in cytoskeleton reorganization“, many of which would be expected based on the
identified gene list. The enrichment analysis for GO
categories was performed using the Database for Annotation, Visualization and Integrated Discovery (DAVID)
program. The top clusters of biological processes and
metabolic functions that are enriched in the set of differentially expressed genes are shown in Figure 5B. The
most highly enriched clusters of the gene ontology categories included vasculature development and angiogenesis, immune responses, cell adhesion, and cell motility
and migration. Vascular development and angiogenesis
is the highest enriched GO cluster in which the ECrestricted genes are overrepresented (Enrichment score
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Figure 2 Colorgram depicting the expression of EC-restricted genes in different cell types in the primary set. The columns represent the
samples and rows represent the genes. Gene expression is shown with a pseudocolor scale (-3 to 3) with red color denoting high expression
level and green color denoting low expression level of the gene. The scatter plots along the heatmap depict the different patterns in expression
of EC-restricted genes obtained using K mean clustering. The K mean clusters are represented as scatter plots with bars denoting the mean
expression level. Pattern I and IV depict a range of expression patterns exhibited by EC-restricted genes. For example pattern IV and I denotes
the genes that are highly expressed in all endothelial cell types (pan EC) and HMVEC cells respectively.
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Figure 3 Expression of ECs restricted genes in REFEXA database. A) Hierarchical clustering analysis of EC-restricted expression genes using
REFEXA gene expression data. The columns represent the samples (primary endothelial and non endothelial cells from REFEXA database) and
rows represent the genes. The detailed information about the primary cells can be obtained from REFEXA database http://157.82.78.238/refexa/
main_search.jsp. Gene expression is shown with pseudocolor scale (-3 to 3) with red denoting high expression level and green denoting low
expression level of gene.
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Figure 4 Validation of a selected subset of endothelial-restricted genes by quantitative RT-PCR. Validation of a subset of EC-restricted
genes from Table 1 was conducted using primary ECs and non-ECs by quantitative RT-PCR (n = 3 per cell type). The gene symbol is listed for
each gene. RQ refers to “relative quantity” where the expression in HUVECs has been set to 1.0 and the relative expression of the other cell
types are compared to that in HUVECs.

4.72). This finding supports the overall concept that at
least a subset of the genes we identified as being ECrestricted have previously been described in processes
known to involve ECs.
Disease set enrichment of EC-restricted genes

In order to evaluate whether the EC-restricted genes are
potentially linked to the pathogenesis of certain human
diseases, we performed a disease set enrichment analysis
using disease sets on the basis of published literature
(DSPL). DSPL enrichment analysis was performed using
the MetaCore tool in the GeneGO package. The disease
associations are summarized in Figure 5C, depicting the
top diseases in which EC-restricted are enriched. The
EC-restricted genes are enriched in the many cardiovascular diseases including ventricular dysfunction, myocardial infarction, hypertension, diabetic angiopathies,
arteriosclerosis, and several other vascular diseases.
Interestingly, ischemia was listed as a disease in which
the EC-restricted are over-represented (P value = 2E06). The EC-restricted genes are also enriched (P value
< 0.01) in neurological diseases including subarachnoid
hemorrhage (P value = 3.00E-07).

Regulatory mechanism governing EC-restricted genes

To begin to understand the complex and intricate regulation of the EC-restricted genes, we were interested in
determining whether certain transcription factors or
miRNAs might be involved in regulating these genes.
Transcription factors play a critical role in defining cell
and tissue specificity of gene expression. In this study
the TFactor enrichment analysis was performed on two
sets of EC-restricted genes categorized on the basis of
expression profiles; the sets of genes are highly
expressed in i); all EC types (pan EC), ii); only in
HMVEC. The TFactor enrichment analysis was only
performed on these two sets as they constitute the
major fraction of EC-restricted genes. TFactor enrichment analysis was performed using the ExPlain tool, a
program for gene expression analysis from BIOBASE.
We performed the analysis on a region 2 kb upstream
to 100 bp downstream of each of the EC-restricted
genes using vertebrate_non_redundant matrices (yes
set). Background frequencies were calculated based on
the promoters of human housekeeping genes (No set)
[12]. A TF binding site was considered to be enriched in
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Figure 5 Enrichment analysis of EC-restricted genes. A) Top enriched Canonical Pathways B) Top enriched GO Processes. C) Top enriched
disease set. The analysis for pathways and disease set enrichment was performed using the MetaCore tool of the GeneGo package. The GO
categories enrichment analysis was performed using the DAVID tool. The Bar graphs depict the enriched pathway or Go process categories and
-log of the P value. The P value depicts the significance of enrichment, the smaller is the P value the more significant is the enrichment. The
pathways and disease sets with FDR adjusted P value < 0.05 are considered significant. The panel for gene ontology enrichment depicts the
enrichments for each GO category (-log P value) as well as the Escore for a cluster of related GO categories.
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a gene set on the basis of the P value (P value < 0.001
and Yes/No > 1.2). The analysis identified binding sites
for >20 transcription factors, among the EC-restricted
genes expressed in all EC, and in the subset enriched
only in microvascular ECs [Figure 6]. Binding sites for
the TF factor that were identified for both of these sets
of genes included, CDXA, GATA, IPF1, NFAT, CDP,
AIRE and OCT1. However, the binding sites for particular sets of transcription factors (e.g. FAC1, POU1F1,
STAT1, AR, SRF, LRH) are only enriched in promoters
of microvascular EC-restricted genes.
Another mechanism by which gene expression can be
regulated is through small noncoding RNAs or microRNAs (miRNA). MiRNAs regulate gene expression
through translational repression of mRNA by promoting
the degradation of mRNA by binding to specific sequences
in the untranslated regions of the mRNA. We performed a
bioinformatics analysis of the EC-restricted genes in order
to identify whether the identified EC-restricted genes are
targets of miRNAs. We used composite regulatory signature database (CRSD) web tools that take into consideration the sequence match and free energy of binding to
predict binding sites [16]. Our analysis identified 31
miRNA binding sites that are significantly enriched (P
value < 0.05) in the UTR of the EC-restricted genes [Figure 7]. Mir-432, Mir-188, and Mir-331 target each have
putative binding sites in the 3’ UTR of >8 EC-restricted
genes. A summary of the miRNA binding sites for ECrestricted genes is provided in Table 2. Additionally details
of miRNA Binding sites along with target and reference
sequences are provided in Additional File 2.
Expression pattern of EC-restricted genes in tissues

A better understanding of how the EC-restricted genes
are expressed in different tissues can help to define their
function and potential use as disease biomarkers. Relative expression of the EC-restricted genes in several normal tissues was obtained using the Source databases
http://source.stanford.edu. In the source database the
normalized gene expression represents the relative
expression level of a gene in different tissues. The colorogram depicting the percentage of relative expression of
each gene is shown in Figure 8. The analysis demonstrates that most of the endothelial restricted genes have
preferential expression in vascular tissues. In particular
MMRN1, BMX, ANGPT2 and CDH5 demonstrate high
expression levels in vascular tissues. VWF, TIE1,
ROBO4 and ECSCR have very high expression levels in
umbilical cord tissue (Table 3). These results strengthen
our finding that these genes have relatively high expression levels in vascular related tissues.
To further explore whether any of the EC-restricted
genes have specific expression in particular tissues, we
obtained the immunohistochemistry data for 61 out of
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the 109 EC-restricted genes. The majority of the ECrestricted genes demonstrate a ubiquitous expression in
different normal tissues (Additional File 3). A small subset of the genes show a restricted expression pattern in
normal tissues. For example, VWF and ICAM2 are
enriched in soft tissues. BMX, one of the top ranked
endothelial restricted genes has preferential expression
in the epididymis. CLDN5 is preferentially expressed in
glandular cells of various body tissues. Interestingly,
about 85% of genes depict moderate to high levels of
expression in soft tissues.

Discussion
The results of our study demonstrate that of over 43,000
transcripts evaluated, only 152 appear to be highly
restricted to the endothelium. Several of the genes identified have previously been reported to exhibit an ECrestricted expression pattern and have known functions
in ECs. Examples of these genes include angiopoietin-2,
von Willebrand’s Factor (vWF), EC nitric oxide synthase
(eNOS), and Pecam-1 (CD31). The pathways, and GO
categories of the identified genes support a role for
these genes in vascular development, angiogenesis, and
EC function.
Although several of the EC-restricted genes have previously been shown to contribute to the regulation of
normal EC function, many others have not been characterized as having a particular role in EC. The genes identified as being EC-restricted fall into several categories,
including proteins involved in transcriptional regulation,
cell adhesion, signal transduction, and intracellular trafficking. The determination that these genes are enriched
in ECs may lead to future studies that define their specific role in regulating EC function.
The endothelium is known to play an important role in
a number of human diseases, and so it was not a surprise
that alterations in the expression of these genes are associated with a number of cardiovascular disorders. Mutations or alterations in the expression of several of the
genes listed have been shown to be associated with the
development of hypertension. For example, mutations in
the eNOS gene have been linked to patients with essential hypertension [21-23]. Similar associations have been
observed with mutations in the endothelin-1 gene
[24,25]. More recent studies point toward a link between
obesity and hypertension. There has been particular
interest at understanding the role of adipocytokines and
their receptors in the development of hypertension. Previous studies have suggested a causal link between leptin
levels in obese patients and the development of hypertension [26]. A more recently discovered adipocytokine, apelin, is predominantly expressed in the ECs of the heart
and support a role for apelin in the development of
hypertension and cardiac hypertrophy [27].
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Figure 6 Regulation analysis of EC-restricted genes. The list of the transcription factor binding sites that are enriched in 2 kb upstream to
100 bp downstream region. The enrichment in gene sets that are highly expressed in all endothelial cells and only microvascular EC is shown in
black and grey color respectively. The X-axis represents the transcription factors and Y-axis represents -log P value.

Figure 7 Regulation analysis of EC-restricted genes in term of MiRNA targets. The list of the miRNA that are enriched in 3’ UTR of EC
specific genes. The X-axis represents the miRNA’s and Y-axis represents -log P value. The miRNAs from the opposite standard of guided RNA
strand are marked with star (*).

The endothelium is known to play an important paracrine role with respect to cardiac function and development. The TGFbeta family member cytokine, bone
morphogenetic protein-4 (BMP-4), is known to play an
important role during cardiac development [28]. Increased

expression of BMP-4 may similarly be reflective of a state
of EC dysfunction. Exposure of ECs to BMP-4 promotes
ROS generation [29]. BMP-4 expression is increased in EC
exposed to abnormal or unstable flow, compared to regions
of laminar shear flow [30]. Venous and microvessel ECs
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Table 2 List of significantly enriched miRNAs binding sites
microRNA

Hits

P-Value

hsa-miR-432*

11

1.53E-04

0.035458796 PALMD,RAPGEF5,LOC90139,MYLK2, CETP,TIE1,GLCE,VWF,ROBO4,KIAA1274, PDE2A,

FDR Gene Symbol,

hsa-miR-188

10

7.60E-04

0.058786382 CDH5,EGFL7,CXorf36,,RNASE1,SEMA6B, ESAM,RGS3,ROBO4,HYAL2,

hsa-miR-132

6

6.39E-04

0.074133993 IL1RL1,CXorf36,LOC90139,SLC29A1, IPO11,LOC116441,

hsa-miR-331

9

0.002161

hsa-miR-296

9

0.001918

hsa-miR-512-5p

8

0.00932

0.166330341 APLN,RAPGEF5,BCL6B,SLCO2A1, LOC400451,KDR,ROBO4,FLJ46061,

hsa-miR-503

8

0.008909

0.172244646 APLN,LOC90139,ESAM,MGC20262, VWF,ROBO4,ZDHHC14,HYAL2,

hsa-miR-518e

5

0.008905

0.187818163 LAMP3,NOTCH4,BCL6B,GLCE,SEMA6B,

hsa-miR-520a*

8

0.008722

0.202353355 EGFL7,FLJ10241,APLN,ABCA4, HSD17B2,SHANK3,ESAM,CGNL1,

hsa-miR-345

8

0.008564

0.220764545 FLJ10241,RAPGEF5,MYLK2,ADCY4, PLSCR4,GJA4,RGS3,PDE2A,

hsa-miR-490

8

0.008331

0.241605345 CDH5,ESAM,MGC20262,ROBO4, FLJ46061,MOV10L1,CGNL1,ICAM2,

hsa-miR-299-3p

5

0.007968

0.264095479 APLN,TNFRSF11A,TIE1, PECAM1,ROBO4,

hsa-miR-328

8

0.007307

0.282532121 EGFL7,CLDN5,CXorf36,LOC90139,SEMA6B, RGS3,ROBO4,KIAA1274,

hsa-miR-525

7

0.029061

0.293137643 EGFL7,FLJ10241,RAPGEF5,NOTCH4, FLJ22746,ESAM,FLJ46061,

hsa-miR-337

7

0.027316

0.301772827 RAPGEF5,FLJ22746,SHANK3, LOC400451,PLSCR4,KIAA1274,

0.10028083 TXNRD2,LOC90139,FLJ22746,BCL6B, SEMA6B,ESAM,KIAA1274,TBX1,ICAM2,
0.111262412 ARHGEF15,CDH5,APLN,RNASE1, SEMA6B,ESAM,ROBO4,CGNL1,

The miRNAs that are expressed at relatively low level as compared to miRNA from opposite/guided standard are marked with star (*).

exposed to BMP-4 rapidly undergo apoptosis [31]. These
results suggest the possibility that BMP-4 could be a possible therapeutic target in the setting of heart failure to
improve or reverse EC dysfunction.
The functional and structural integrity of the central
nervous system depends on tightly controlled coupling
between neural activity and cerebral blood flow. This
requires the close interaction of neuronal cells and vascular cells in a complex that is known as the neurovascular unit. Recent experimental evidence suggest that
dysfunction of the neurovascular unit may be an early
event in Alzheimer’s disease. Studies in transgenic mice
overexpressing the amyloid precursor protein (APP)
exhibit abnormalities in blood flow in response to functional hyperemia prior to the development of amyloid
plaques or vascular amyloid [32]. Administration of
soluble amyloid beta protein results in vasoconstriction,
EC dysfunction and a reduction in CBF. One of the
main mechanisms by which EC dysfunction occurs is
through inactivation or reduced function of EC nitric
oxide synthase (eNOS). Amyloid beta also induces the
production of reactive oxygen species, alteration in the
expression of tight junction proteins, and an increased
rate of EC apoptosis [33]. In the brain tissue samples
of patients with AD, we observed a significant increase
in the expression of selected adherens and tight junction proteins including VE-cadherin, claudin-5, and
connexin 37 (GJA4). Systemic administration of the
amyloid beta peptide 1-42 to rats is associated with
alterations in the expression and cellular localization of
several tight junction proteins [33]. Another ECrestricted gene found to be significantly upregulated in
the AD brain tissue samples is von Willebrand’s Factor

(vWF). Increased levels of vWF promote blood clotting.
Increased vWF has been found in heme-rich deposits
(HRDs) in patients with dementia [34]. HRDs are also
rich in fibrinogen, collagen IV, and red blood cells, and
are thought to be the residua of capillary bleeds, or
microhemorrhages. In patients with acute ischemic
stroke and vascular dementia, vWF levels have also
been shown to be increased [35].
Our analysis of potential transcription factors that
might be involved in regulating the expression of the
identified EC-restricted genes, based on conserved
binding sites in the regulatory regions of these genes
led to the identification of several classes of transcription factors. Most of these transcription factors have
not previously been described as playing a major role
in the regulation of EC-restricted genes with some
exceptions. Members of the ETS and GATA transcription factor families have been shown to regulate a
number of endothelial genes including vWF, VE-cadherin, and Tie1 [36-38]. Interestingly, several conserved binding sites were identified only in the
regulatory regions of the microvascular ECs suggesting
that members of these transcription factor families
may play a unique role in determining endothelial
gene expression in microvessels.
Over the past several years a role for microRNAs has
been demonstrated to play a role in regulating EC gene
expression, function, and in the process of angiogenesis.
Although most of the miRNAs we identified have not
been described for their roles in regulating EC-restricted
genes, a few have. For example, hsa-miR-296 has
recently been shown to play a regulatory role in angiogenesis (39). Angiogenic factors can increase the
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Table 3 Normalized Expression Level of top endothelial
restricted genes obtained from the Source database
Gene Symbol

Rank Score

Normalized Expression

MMRN1

11157.50625

Vascular (29.44%)
Umbilical cord (16.7%)

CLDN5

5933.421875

Adipose (66.3%)

VWF

4772.862931

Umbilical cord (43.9%)

BMX

4447.913846

Vascular (56.1%),
Umbilical cord (10.1%),
Ganglia (11.8%)

ANGPT2

1412.88625

Vascular (19.2%),
Umbilical cord (16.3%),
Placenta (12.5%)

GJA4

1284.435

Adipose (24.4%),
Placenta (10.8%),
Ganglia (9.3%)

CDH5

1115.751864

Vascular (19.6%),
Placenta (29.4%)

TIE1

1107.308411

Umbilical cord (16.0%),
Ganglia (22.2%)

ROBO4

975.358913

Umbilical cord (82.4%)

ECSCR

646.6127586

Umbilical cord (44.6%)

The relative expression level of the genes in different tissues is expression as
percentage. The gene expression data for generating the normalized
expression level was DbEST database of normal tissues at NCBI.

expression of hsa-miR-296. Down regulation of hsamiR-296 in ECs inhibits angiogenic responses in cultured ECs. Furthermore, inhibition of hsa-miR-296 with
antagomirs reduced angiogenesis in tumor xenografts in
vivo. Similarly, hsa-miR-328 has been implicated in the
regulation of CD44 [39]. CD44 regulates a wide variety
or processes including angiogenesis and inflammation.
The fact that only a small subset of the more than 700
microRNAs has thus far been shown to regulate ECrestricted genes or play a role in regulating EC function
suggests that several additional members, including
those we have identified, may well also play a role in
regulating the expression of selected EC-restricted genes
or EC function.
We recognize that there are potential limitations of
our study. First, the study used expression-profiling data
based on RNA obtained from human tissues or cells.
Although several of the genes identified are known to
be vascular-specific, the newly identified genes will ultimately need further validation as to the true extent of
their EC specificity, at the level of protein and/or RNA
both in cells and tissues, and to validate their ECrestricted pattern within the identified tissues.
Figure 8 Relative normalized expression levels of EC-restricted
genes in normal tissues. The expression level is expressed as
relative percentage of expression in different tissues with red, yellow
and green color denoting higher, median and lower expression
levels respectively. The rows represent each gene and columns
represent each normal tissue type.

Conclusion
Our study validates the existence of a finite number of
endothelial-restricted genes most of which are ubiquitously expressed. Several of these are restricted to cells
of microvascular origin. Although several of the genes
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are known to play important roles in endothelial function, the exact functional role of many others in
endothelial cells remains to be defined. We hope that
our study provides an initial catalogue of EC-restricted
genes that can lead to further studies that either link
alterations in the expression of these genes to a variety
of human diseases via their role as biomarkers or are
ultimately shown to play a causal role in the pathogenesis of the particular human diseases.
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10.
Additional file 1: Nucleotide sequence of primers used for RT-PCR
to validate expression pattern of selected EC-restricted genes.

11.

Additional file 2: Summary of miRNA Binding sites along with
target and reference sequences.
Additional file 3: Immunohistochemistry based expression level of
genes in different tissues. Rows represent the different tissues and
columns represent the different EC-restricted genes. The expression level
is shown in four color circle scheme i) Red represents strong expression
ii) Orange represents moderate expression, iii) Yellow represents weak
expression, iv) White represents no detectable expression and Black
represents no representative images. The data was obtained from human
protein atlas database.
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